Nanobiotix (NASDAQ:NBTX) Hits New 52-Week High - Here's Why

Key Points

• Nanobiotix's stock reached a new 52-week high at $13.43, closing at $12.86 with strong trading activity.
• Analysts have rated the stock as a "Moderate Buy" with an average price target of $11.00, indicating potential growth following a buy rating restatement by HC Wainwright and a price target increase by Leerink Partners.
• An institutional investor, Jane Street Group LLC, acquired 23,283 shares of Nanobiotix, demonstrating growing institutional interest in the company.

Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $13.43 and last traded at $12.86, with a volume of 100565 shares traded. The stock had previously closed at $11.57.

Wall Street Analysts Forecast Growth

NBTX has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating on shares of Nanobiotix in a research note on Friday. Leerink Partners set a $14.00 price target on Nanobiotix in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $11.00.

Nanobiotix Trading Up 11.1%

The company has a 50 day simple moving average of $8.13 and a 200 day simple moving average of $5.39.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC purchased a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,283 shares of the company's stock, valued at approximately $73,000. Institutional investors own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.